This review on the role of neurofilaments as surrogate markers for axonal degeneration in neurological diseases provides a brief background to protein synthesis, assembly, function and degeneration. Methodological techniques for quantification are described and a protein nomenclature is proposed. The relevance for recognising anti-neurofilament autoantibodies is noted. Pathological implications are discussed in view of immunocytochemical, cellculture and genetic findings. With reference to the present symposium on multiple sclerosis, the current literature on body fluid levels of neurofilaments in demyelinating disease is summarised.
Introduction
The cytoskeleton of the axon is made of a scaffolding of proteins. Out of these the most important are the neurofilaments. Neurofilaments are an architectonic amazingly stable tube system of about 10 nm diameter. This size places them intermediate between the smaller microfilaments (7 nm) and the larger microfilaments (≈ 25 nm). Nf are classified as type IV intermediate filaments [1] (Table 1) . To fully appreciate the structural achievement of this protein in cellular architecture one must put the size of neurons and axons into relation. The neuronal cell-bodies (0.01 to 0.05 mm size) are connected by axons of over 1m length (the axonal diameter is 1 to 25 µm). This is a factor of 100,000 difference. How does the neuron achieve to maintain this enormous structure, more importantly, how can the breakdown of the axon be detected and related to disease?
This review focuses on 4 parts; firstly the neurofilament (Nf) subunit synthesis, its assembly into tubular structure and the post-translational modifications with particular reference to phosphorylation; secondly on methodological quantitative techinques; thirdly on clinico-pathological relationships related to Nf disassembly including accumulation, phosphorylation and disease; and finally the potential of Nf to serve as surrogate markers for axonal injury, disintegration and loss with particular reference to multiple sclerosis. The formation of the typical IF of 10 nm diameter is determined by the correct assembly of the NfL, NfM and NfH subunits. The assembly of the three Nf subunits is dependent on the N-terminal head region. NfL is known to polymerise on its own in vitro, while NfM and NfH cannot [10] . However, both NfM and NfH can co-assemble with NfL in vitro [11] . Assembly occurs in 5 stages: polypeptides are wound around each other to form dimers which are sorted in an antiparallel fashion in order to form tetramers, protofilaments and finally IF (Figure 2 ). The α-helical coiled-coil parallel heterodimers contain NfL and either of NfL, NfM or NfH [12] . Ultrastructural analysis of the NfL assembly process reveal that the lateral association of the protofibrils is promoted by the head-domain and terminated by the tail-domain [13] . In vivo Nfs are obligate heteropolymers [12] .
Phosphorylation
The neurofilament heavy chain is the most extensively phosphorylated protein of the human brain, and possibly the entire human body. Phosphorylation and dephosphorylation of the neurofilament proteins is a complex process which is predominately regulated within the axonal compartment and targeted on different phosphate acceptor sides in the Nf subunits ( Figure 3 ) [14, 15] . NfM and NfH become highly phosphorylated post-translationally after being transported from the neuronal cell soma in the axon. In vivo phosphorylation of Nf is slow, orchestrated by a range of enzymes and has recently been reviewed in detail by Grant & Pant [16] . In brief, enzymatic phosphorylation is predominantly subject to 2 types of kinases: the non-proline directed and the proline directed (i.e. cyclin-kinases and MAP kinases).
Phosphorylation of the C-terminal tail domain is thought to occur at the side arms protruding from the assembled filaments. The C-terminal tail domain consists of Figure 3 . The main phosphorylation sites of different kinases on the three Nf proteins are shown (adapted from [16] ).
NfH
42 KSP (Lys-Ser-Pro) repeats in humans [17, 18, 19] . Phosphate is coupled with high affinity to serine within the KSP repeats [18, 19] . An additional phosphate acceptor site with high binding affinity is threonine [16] .
The N-terminal domain is phosphorylated by glycogen synthetase kinase-3 [20, 21] , extracellular signal-regulated kinases [22, 23] and cyclin-dependent kinase-5 [14, 24, 25] .
Phosphorylation of the C-terminal domain is regulated by a range of protein kinases [6, 26, 27] .
Glycosylation The NfL (Ser27, Thr21) and NfM (Thr48) head region are posttranslationally modified by adding on O-linked N-acetylglucosamine moieties [28] . All these locations are essential for in vivo Nf assembly. O-GlcNAc modification has also been reported for the NfH KSP repeats [29] , but the precise sites have not yet been identified. It is possible that glycosylation plays a role in Nf trafficking and function.
Terminology Since the use of specific monoclonal antibodies permits us to detect distinct Nf epitopes, the distribution of different NfH phosphoforms was studied in axonal pathology and in neurodegeneration. It is against the background of this research that Sternberger et al. (1985) proposed the classification of the antibodies, recognising these NfH phosphoforms according to their cellular distribution into 4 groups: Group I antibodies stain cells and structures in the grey matter, Group II antibodies stain for projecting axons, but not for neuronal perikarya, dendrites or proximal axons, Group III antibodies stain for perikarya, dendrites and proximal axons and Group IV antibodies stain for all structures revealed by group II and group III antibodies [30] .
However, in the literature reference is commonly made to non-phosphorylated or hypophosphorylated versus hyperphosphorylated or extensively phosphorylated, with phosphorylated being the assumed dominant (normal) NfH phosphoform. The use of mass-spectroscopy permits the identification of the phosphorylation sites within the protein [18, 19] . This requires labour-intensive pre-analytical purification of Nf sub-units [18] and because of conformational changes correct identification of non-linear epitopes cannot be guaranteed. [31] . For each antibody the name of the clone and the source need to be provided. This terminology facilitates comparisons of results between studies and across methods (i.e. immunoblotting, immunocytochemistry and ELISA).
Function About 80% of axonal Nf are highly phosphorylated and integrated by cross-linking in the axoskeleton, thus constituting the "static pool" [32] . The remaining 20% of less extensively phosphorylated Nf constitute the so called "dynamic pool" [33, 32] .
Because phosphorylation alters the charge of the side-arms, it was proposed that one function of phosphorylation is to increase the charge-based repulsion of neighbouring filaments, thereby increasing inter-filament spacing and consequently increasing axonal calibre [34] . The close relation of axonal diameter and conduction velocity [35, 36] is of physiological relevance.
However, radial axonal growth does not depend on mechanisms of NfH phosphorylation alone [37] and the original hypothesis, that phosphorylation of NfH sidearms is essential for Nf spacing and radial axonal growth, has been modified in that Nf subunits interact stoichiometrically and NfM is the "preferred" subunit for NfL copolymerisation and main regulator of radial axonal growth [38, 39, 40, 41] . It also seems that NfL and NfM stoichiometrics are more important for axonal growth than NfH phosphorylation. This notion is substantiated by knockout mice experiments [38, 41, 42, 43, 44, 14, 45] (for review see [16, 14] ). It was suggested that small side-arms extend from non-phosphorylated NfH, but extend much further with phosphorylation and charge-related uncoiling of the KSP repeats [46] . Whilst non-phosphorylated NfH adhere to microtubules, probably in competition with tau, phosphorylation leads to dissociation from the microtubules [47, 48] . Other IFinteracting proteins are mainly from the plakin family (i.e. the bullous pemphigoid antigen-1 proteins (BPAG1), ACF7, desmoplakin, envoplain and periplakin), the dynein/dynactin complex, myosin Va and probably the D(1) dopamine receptor (reviewed in [49] ). Lee and Cleveland suggested that "the phosphorylation process is ultimately linked to, and may be regulated by, myelination." [3, p. 204 ].
The importance of local phosphorylation for regulating Nf assembly is highlighted by the observation that the formation of protofibrils is inhibited if the NfL head domain becomes phosphorylated [50, 51] . In fact phosphorylation of the NfL head domain at Ser55 or the NfM head domain at Ser44 by protein kinase A (PKA) is sufficient to block Nf assembly [6, 27] .
The relatively small (≈ 20%) "dynamic pool" of non-or hypophosphorylated NfH [33, 32] is involved in ante-and retrograde axonal transport [52] .
Axonal transport
The initial studies of axonal transport of Nf using radiographic labelling [53, 54, 55] suggested a velocity of ≈ 0.25-3 mm/d which is slower than any speed produced by known molecular motors [56, 49] . Recent studies using green-fluorescent-protein (GFP)-tagged Nf subunits and real-time confocal microscopy show more accurately that the conventional fast axonal transport also applies to Nf. Peak velocities of 2 /second occur antero-and retrograde and are interrupted by prolonged resting phases resulting in the overall slow transport originally described (reviewed in [57, 49] ).
The degree of phosphorylation correlates inversely with the velocity of axonal transport [58, 59, 60] . It has been suggested that this is due to phosphorylation dependent dissociation of Nf from the kinesin motor [61] .
Accumulation of Nf has been shown in a range of diseases. Recent work using GFP-tagged NfM demonstrated in cell-culture (SW13) that treatment with glutamate slows axonal transport and leads to neuronal accumulation of NfH SMI36 [62] . This finding supports the concept that glutamate-induced excitotoxicity might contribute to the pathogenic process in some neurodegnerative diseases.
Degradation It is believed that Nf are broken-up when they arrive at the axon terminus. The breakdown of Nf depends on protease digestion [63, 64] . Under physiological conditions this is mediated by calmodulin, a Ca 2+ -dependent protease [65] . Susceptibility of Nf to protease digestion decreases with increase of phosphorylation [66, 67, 68] . This has analytical implications, particularly for NfL and the non-phosphorylated forms of NfM and NfH in protease-rich body fluids such as the cerebrospinal fluid (CSF).
Lee and Cleveland calculated the life-time of Nf to be around 1-2 years, based on calculating the transit time through the human sciatic nerve at a daily rate of 1-2 mm/day [3, p. 202] . Because of this long-life Nf are very likely to accumulate damage caused by oxidative stress, inflammation, etc. which could ultimately lead to disturbed filament assembly, accumulation and axonal pathology.
There might be a biological reason why NfL is more susceptible to protease activity then NfH and NfM. The potential of NfL to polymerise on its own could result in protein accumulation, aggregate formation and disease.
Methodological approaches
At present three methodological approaches have been undertaken in an attempt to quantify Nf: (1) Western / immunoblotting techniques [67, 69] , (2) a dot-blot immunoassay [70] and (3) ELISA techniques [71, 72, 31, 73] .
Western & dot blotting Although of qualitative advantage for distinguishing NfH phosphoforms and breakdown products, the Western/immuno-blotting techniques have never been adopted on a clinically relevant scale. This is partly due to the semiquantitative and labour intensive nature of the method. It is particularly difficult to overcome the densitometric limitations of highly sensitive methods such as chemiluminescence because of the high gamma of photographic paper which results in a steep standard curve with a very small linear range. New charged-double device (CDD) cameras which enable one to obtain serial images could help to overcome this problem [74] . The trouble with a dot-blot approach is specificity which impacts on CV and reproducibility. In contrast the ELISA approach provides the highest analytical accuracy and is ideal for a high throughput of samples.
ELISA Two Nf subunits have been investigated in human body fluids using ELISA: NfL [71, 73] and NfH [72, 31] . The Lars Rosengren group concentrated for over 10 years on NfL with good reason: this Nf protein is considered to represent the most abundant subunit, hence the term "backbone" of the Nf polymer. It also is the smallest and most soluble subunit. These requirements would make it an ideal candidate for a surrogate marker if it were not for some concerns about its susceptibility to proteases, particularly in the protease-rich CSF. Thus rigorous sample handling is recommended (i.e. snap-freezing of the CSF at the bedside).
Because of the associated logistical problems our group has concentrated on NfH, which in its phosphorylated state is more resistant to proteases [66, 31, 67, 68] . Additionally NfH phosphorylation is of functional importance in axonal pathology. Information on the quantitative relationship of NfH phosphoforms might provide further insight in the dynamics of axonal injury and thus contribute to our understanding of neurodegenerative diseases.
Autoantibodies It is of note that the presence of neurofilament auto-antibodies has been observed by several groups [75, 76, 77, 78, 79] , mainly in chronic diseases. Because Nf auto-antibodies potentially decrease body fluid antigen levels, they could influence the quantification of Nf by ELISA or other methods and should ideally be measured in order to allow for a balanced interpretation of the data.
Axonal pathology
Nf subunits are actively involved in the pathogenesis of axonal dysfunction and degeneration both as causative agents for disease and as markers for disease progression.
Neurology of Nf
It has been suggested the neurology of Nf be classified into disorders of Nf synthesis, phosphorylation, distribution by axonal transport, and their breakdown [80] .
The accumulation of Nf proteins has been observed in amyotrophic lateral sclerosis (ALS, synonymous with motor neuron disease) [81] , spinal muscular atrophy [82] , Parkinson's disease (PD), some dementias (as a component of Lewy bodies together with α-synuclein), Alzheimer's disease (AD), progressive supranuclear palsy (PSP), diabetic polyneuropathy and giant axonal neuropathy [83] .
Multiple sclerosis In MS, axonal injury has been related to increased staining by NfH
SMI32 [84, Figure 8B ]. NfH SMI32 was particularly abundant in axonal ovoids which indicate the site of axonal transection. With regard to cortical lesions Bö provided evidence for axonal loss by demonstrating the frequent occurrence of ovoids. Interestingly, and in contrast to the finding by Trapp et al. [84] , the intensity of staining of non-phosphorylated NfH (NfH SMI32 ) was reduced in most cortical regions of axons with myelin loss, whilst staining for phosphorylated NfH (NfH SMI34 ) increased [85] . One might speculate that this difference in patterns of NfH phosphorylation reflects differences in patterns of damage, i.e. Wallerian degeneration in white matter pathology versus dying back neuropathy in grey matter pathology.
Alzheimer's disease In AD, increased staining for phosphorylated NfH is evident in the proximal axon and the perikaryon [30, 86, 87, 88] . The NfH phosphorylation in axons elongating from AD plaques is particularly intriguing and has been interpreted as evidence of early axonal injury caused by toxic properties of the plaque [67, 87, 88] . Others provided evidence that NfH SMI32 positive neurons are selectively lost in AD [89, 90, 91] . This finding was supported by demonstrating kainate-dependent hyper-vulnerability of NfH SMI32 positive neurons [91] .
Amyotrophic lateral sclerosis In ALS, increased staining for phosphorylated NfH (i.e. NfH SMI34 , NfH SMI35 ) has been shown in axons and the neuronal cell bodies. There is evidence for accumulation of phosphorylated NfH in the degenerating motor neurons [81, 92] . However, Nf dephosphorylation has also been reported to precede excitotoxicity in a spinal cord cell culture model of ALS [93, 94] . Extending this work, the same group has recently reported an increase in staining for NfH SMI32 of cultured spinal cord neurons after exposure to CSF from patients with ALS [95] . Interestingly 3 of the 6 control CSF samples were from patients with MS, but the breakdown of the individual data was not published [95] . The implications of Nf aggregation, mainly in the neuronal cell body, is a prominent feature of ALS and has been studied in depth mainly by Jean Pierre Julien's group using the gain of function SOD− mouse (for review see [96, 97, 98, 99] ). It seems that somal accumulation is preceded by disruption of axonal Nf transport due to stoichiochemical imbalance of the Nf subunits. However the pathological implications of somal accumulations are not entirely clear and the same group holds a patent protecting one approach to using Nf phosphorylation as a neuroprotective strategy.
Cerebrovascular pathology
In stroke, Hedreen and colleagues demonstrated accumulation of phosphorylated NfH (NfH SMI35 , NfH SMI34 , NfH SMI31 ) in neuronal cell-bodies and dendrites which were likely to have suffered from axonal disconnection in stroke (i.e. in the thalamus and cerebral cortex) [100] . This phenomenon was observed up to 2 months after a stroke. The authors suggested impaired axonal transport as the pathological correlate. In a recent study on intracranial and subdural haemorrhage we found an increase of the phosphorylated (NfH SMI34 , NfH SMI35 , NfH SMI310 ) but not of the non-phosphorylated (NfH SMI310 ) protein [101] .
Glaucoma
The monkey model of glaucoma is the only other condition apart from MS [84] where, to the best of my knowledge, increased staining of nonphosphorylated NfH has been related positively to axonal loss [102] . Kashiwagi and colleagues stained the optic nerves for SIGMA NF-200 (NfH NE14 ) and NfH SMI31 .
The
NfH SMI31
NfH NE14 ratio was used to calculate the phosphorylation status (a high ratio indicating a high degree of phosphorylation). In the glaucomatous eye there was a decrease in staining for NfH SMI31 in the retina, the optic disc and optic nerve reaching as far back as the optic chiasm. There was a 4-fold difference in the degree of phosphorylation in all but the nasal retina, ranging from ≈ 21-53% in the glaucomatous to 85-97% in the control eyes. This semiquantitative finding is supported by Western blot analysis showing a stronger band for NfH SMI32 in tissue homogenate from the glaucomatous eye. The authors speculate that this might be related to disturbance of axonal transport, a well known phenomenon in glaucoma, but leave it open as to whether NfH dephosphorylation is "the chicken or the egg" in this process [102] . Charcot-Marie Tooth disease CMT is an inherited neuropathy comprising a range of genetic classifications (for review see [103, 104] ). The axonal form (CMT2E) has been associated with mutations in the rod domain of the NfL subunit [105, 106, 107, 108, 109] (Figure 4) . Mutation close to the NfL rod-domain causes an increase of neuronal NF-L due to impaired Nf assembly [110] . Whether the problem is primarily due to increased axonal vulnerability caused by impaired axonal transport [110] or to cytoskeletal instability remains to be clarified.
Parkinson's disease
In PD a single case report with a point mutation in the rod domain of NfM has been reported [111] . However, three unaffected members of this family also carried the same mutation. The link between genotype and phenotype remains to be proven.
Diabetic neuropathy This is mostly of the symmetrical sensory distal axonal type. An increase of Nf phosphorylation has been observed in humans [112] and in the lumbar dorsal root ganglia of rats with streptozocin-induced diabetes [113] . It has been suggested that activation of c-Jun NH2-terminal kinase (JNK) plays a role in this process.
Giant axonal neuropathy
The hallmark of giant axonal neuropathy (GAN) is the segmental axonal accumulation of Nf [83] . This is due to multiple mutations on chromosome 16q24.1 encoding for gigaxonin [114] . Gigaxonin is a 597-amino acid BTB (Broad-Complex, Tramtrack and Bric-a-brac)/Kelch protein. It has been suggested that gigaxonin serves as an IF association protein [80] . Gigaxonin disruption leads to Nf disorganisation and massive multifocal Nf accumulation.
Miscellaneous conditions Giant axonal swellings have also been observed in iminodipropionitrile (IDPM) and 2,5-Hexanedione (glue-sniffing) neuropathy [80] . Others observed increased NfH phosphorylation in opiate addiction in humans [115] and mice [116] .
NfH phosphorylation status and disease
In order to obtain more information on the NfH phosphorylation status several authors stained for phosphorylated (e.g. NfH SMI34 ) and non-phosphorylated (e.g. NfH SMI32 ) pre-and post-enzymatic dephosphorylation with alkaline phosphatase (ALP) [117, 67, 30, 118, 119, 87, 88, 119, 86] . The results of these experiments have been summarised for the non-phosphorylated NfH SMI epitopes in Table 2 & 3. For each NfH phosphoform the antibody source and main effects as observed by immunocytochemistry were summarised with regard to ALP-treated versus nontreated tissue sections. Because the applied method of dephosphorylation varied considerably (e.g. incubation times from 2.5 to 18 hours), the protocol is referred to in the footnotes of Tables 2 and 4 . It is worthwhile remembering that ALP used in all of these experiments was not 100% pure and a certain degree of NfH proteolysis due to contamination with proteases is possible, particular for the longer incubation periods (i.e. 18 h at 32
• C).
The results are contradictory, on one side non-phosphorylated NfH (i.e. NfH SMI32 ) seems to indicate either vulnerable neurons or injured axons in diseases such as MS, glaucoma, ALS and AD [84, 93, 94, 95, 89, 90, 91] . On the other side phosphorylated NfH (i.e. NfH SMI34 or NfH SMI35 ) is related to axons injured by plaque toxicity, to neurofibrillary tangles (NFT) [120, 87, 88, 30, 86] , an axon-proximal finding in dementia [119, 92, 81, 30, 87, 88, 86] , indicative of axonal damage in stroke [100] , a hallmark of GAN [83] .
The puzzle of whether increased or decreased Nf phosphorylation indicates axonal injury is unsolved. The field is open to speculation on disease chronicity, impairment of axonal transport, enzymatic imbalance, etc. Figure 5 . Levels of NfH SMI35 ng / mg protein in homogenised neurons, astrocytes and microglia (mean±SD). Adapted with permission from [31] .
Anti-Nf auto-antibodies
chronic diseases where accumulation of axonal degeneration leads to continuous Nf release and consequently to stimulation of the humoral immune-system. These may interfere with ELISA.
Nf-autoantibodies have been found in multiple sclerosis [75, 76] , as a cause for conduction block in neuropathy with monoclonal gammopathy of undetermined significance [77] , in patients with rheumatoid arthritis and neuropathy [78] and in ALS [79] . It is beyond the scope of this manuscript to review the literature of antiNf autoantibodies other than reminding readers of their existence.
Cross-validation of quantitative approaches estimating axonal loss
For a Nf ELISA to be used for estimating axonal degeneration and loss in vivo, two experiments need to be carried out: firstly it must be shown that Nf is present exclusively in the neuro-axonal compartment, thus Nf cannot be released from other cell-types (cell-type specificity); secondly a correlation should exist between tissue axonal count and Nf levels in tissue homogenate.
Cell-type specificity was demonstrated for NfH SMI35 using primary neuronal, astrocytic and microglial cell-cultures ( Figure 5 ) [31] . However after publishing the method I noticed a report on the presence of NfH in T-lymphocytes [130] and embryonic heart muscle [131] . Thus proof that all body fluid NfH SMI35 is truly due to axonal disintegration remains to be obtained. Whilst contamination might be negligible for the CSF this is an important experiment to be carried out for interpretation of blood levels of any of the Nf subunits.
A qualitative rather than quantitative relationship between axonal loss in spinal cords from mice with chronic relapsing experimental autoimmune encephalomyelitis (CREAE) was demonstrated [132] . Figure 6 (A) demonstrates the near complete loss of axonal continuity, presence of axonal end-bulbs and almost abolished axonal presence in the atrophied spinal cord from CREAE mice. Analysis of this spinal cord tissue homogenate showed that levels of NfH SMI35 corrected for the amount of total protein were significantly lower in CREAE animals compared to controls, suggestive of axonal loss ( Figure 6 ).
Nf as a surrogate marker for axonal injury in MS
The hypothesis underlying the measurement of Nf as a surrogate marker for axonal damage is outlined in Figure 7 . The following headings are arbitrary and only intended for didactic purposes. Figure 7 . Neurofilaments are released into the extracellular fluid during axonal disintegration following axonal injury. Conduction block (e.g. by anti-NfH autoantibodies [77] ) and demyelination are potentially reversible whilst axonal loss is not.
CSF NfL studies
The acyclovir trial The first paper investigating the potential of Nf as a surrogate marker for axonal injury in MS was published by Lycke and colleagues. The authors measured NfL CSF levels in patients with relapsing remitting disease participating in a trial with acyclovir [133] . These 60 patients had a mean disease duration of 5.8 years, a mean age of 33 years and an EDSS of < 4. None of the controls (11 healthy volunteers) and 78% of the RRMS patients had detectable CSF NfL levels. Absolute values were not given, but estimating from [133, Figure 1 ] mean CSF NfL levels are about 990 ng/L in the first month after relapse and level at ≈ 200-400 ng/L three months later.
The acute relapse study In a subsequent paper the same group obtained ethical approval to recruit 66 MS patients and 50 healthy volunteers (blood donors) for CSF sampling [134] . 23 patients suffered from a relapse (RRMS-rel) in the 3 months prior to sampling, 18 were in remission (RRMS-rem) and 25 had SPMS. The SPMS patients were older (mean 47.7 years) than the RRMS-rel (32.4), RRMSrem (47.7) and controls (35.4) . CSF NfL was determined using the same ELISA method as in 1998 [71] , the only difference being that non-detectable values were substituted by 125 ng/L (the assay's sensitivity) [134] . CSF NfL levels were detectable in 8% of the controls, 48% of SPMS, 44% of RRMS-rem and 91% of RRMS-rel. Absolute values for the subgroups were not given, but estimating from [134, The MS siblings study The retrospective study aimed to investigate whether individuals with MS immunopathic trait showed early biochemical signs of early involvement of axons [135] . A total of 47 MS patients, 47 siblings (9 with MS trait) and 50 healthy controls (presumably the same as in [134] ) were included. The new NfL ELISA Using a new ELISA method Rosengren and colleagues found CSF NfL levels above cutoff (100 ng/L determined as mean + 3 SEM of the control group) in 2/11 (18%) healthy volunteers (mean±SEM 31±23 ng/L) and 4/5 (80%) of RRMS patients (2,500±1,500 ng/L) [73] .
The dot-blot study Another group investigated NfL levels using a dot-blot immunoassay [70] . Sixteen patients with RRMS, 13 with SP MS and 6 with PPMS have been included. 
CSF NfH SMI35 studies
The NfH ELISA CSF NfH was also measured in 36 patients with laboratorysupported demyelinating disease (MS, CIS, ON) [31] . Based on a cut-off of 0.73 ng/mL derived from 416 patients with other neurological diseases only 1/36 (3%) had pathologically high CSF NfH levels, with the median level being 0.27 (0-0.36) ng/mL. The relapse free interval of this group was not recorded but all patients underwent diagnostic lumbar puncture following acute onset of neurological symptoms suggestive of a relapse-proximate LP.
The Amsterdam cohort -baseline The patients in the Amsterdam group had more benign MS than the above group, and were recruited following an announcement in response to an appeal in the periodical of the Dutch MS Society [76] . CSF NfL levels were non-detectable in this cohort. This might be due to the more benign disease course or to the sensitivity of the NfL ELISA used.
The Amsterdam cohort -3-year follow-up Three year follow-up data was available from 34 of these patients, but only 29 agreed to a second LP [136] . 318 patients with non-inflammatory neurological disease were included as controls (it was not considered to be ethical to perform a lumbar puncture in healthy volunteers). The mean age was 44.0 years for NfH SMI35 controls and 45.4 years for NfH SMI34 controls. The age of the MS patients was 46.5 years for the entire cohort, 39.6 years for RRMS, 48. 
The higher CSF NfH
SMI35 and NfH SMI34 levels in the control group compared to MS patients is in line with the previous finding [31] that axonal injury in MS seems not to be such a major pathology as observed in other neurological diseases. Because each group used different standards it is impossible to compare the absolute values. Even within the same group values between 2 different NfL ELISA techniques differed [71, 73] .
Plasma NfH
SMI35 studies
There are only 2 studies investigating plasma NfH SMI35 levels [137, 138] . The results should therefore be regarded with caution until confirmed independently by other groups, particularly with regard to cell-type specificity as mentioned above.
Acute optic neuritis This prospective study aimed to investigate the relationship between loss and recovery of optic nerve function with surrogate markers for inflammation and for axonal injury in patients with acute optic neuritis [137] . The median plasma levels of NfH SMI35 were significantly higher in the ON patients 170 (70-330) pg/mL compared to the controls 5 (0-94) pg/mL. In total 50% of ON patients had plasma NfH SMI35 levels above cut-off (top value of controls). Plasma NfH SMI35 levels were also higher in those 36% of patients with poor recovery of visual function (250 pg/mL) when compared to those with good recovery (9 pg/mL).
The Toulouse cohort This observational study included 30 MS patients with RRMS treated with interferonβ and aimed to investigate whether treatment response could be related retrospectively to axonal and inflammatory pathology as measured by surrogate markers [138] . There were 11 responders to treatment and 19 non-responders. Median plasma NfH SMI35 levels were significantly higher in the responders 300 (0.1-2,400) pg/mL and non-responders 500 (0.1-2,200) pg/ml if compared to healthy controls 4.5 (0-31) pg/mL. This result remained significant on a categorical level where 58% of the responder and 72% of the non-responder had levels above cut-off (top value of controls).
Correlation with disability scales
A weak correlation between CSF NfL and the EDSS was observed in the "acyclovir trial" at baseline (Spearman's R=0.27, p<0.05) and after 2 years (R=0.34, p<0.01) but the graphs displaying this correlation were not presented [133] and no such correlations were found in the "acute-relapse study" [134] .
The "dot-blot study" revealed a correlation of CSF NfL with the EDSS (Pearson's R=0.41, p<0.05) if only those patients with progressive disease (SP/PPMS) were subjected to analysis [70] . The graphs displaying this correlation were not shown and one might argue that the significance of this correlation would be lost after Bonferroni correction for multiple comparisons.
The "Amsterdam 3-year follow-up study" revealed a correlation between CSF NfH SMI35 levels and the EDSS (R=0.54, p<0.01), an ambulation index measuring gait (R=0.42, p<0.05) and the 9 hole PEG test (R=0.59, p<0.01). However, no such correlations were found at baseline in either the original cohort (n=54) [76] or the baseline values of the subgroup with 3-year follow-up data (n=39, unpublished data).
The "acute optic neuritis study" demonstrated a negative correlation between NfH SMI35 and visual acuity (VA) at the time of first presentation (R=-0.67, p=0.01) [137] .
Although it might be desirable from a publishing point of view to find a correlation between a clinical scale and CSF Nf levels, one needs to remember that not each lesion in the CNS translates into deficit on a clinical scale. Additionally some clinical deficit might be caused by demyelination or conduction block alone. From a clinical point of view it would be more important to identify those patients who are "at risk" of developing progressive disease due to axonal loss with subsequent progression of disability. From a trial point of view rigorous inclusion criteria (i.e. patients with early evidence for axonal degeneration) would help to avoid the potential for selection bias in treatment trials for neuroprotective drugs by cohort contamination with patients showing evidence for inflammation only (prone to bias by regression to the mean).
Nf auto-antibody levels The work on anti-NfL and anti-NfH autoantibodies has largely been done by E Silber using bovine NfL and NfH in an ELISA setup [75, 76] . He discovered a 2-fold higher mean anti NfL index in PPMS (466) and SPMS (499) patients compared to RR MS patients (208) or inflammatory controls (169) [75] . For the anti NfH index the differences were less marked RRMS (381), PPMS (455), SPMS (501) and inflammatory controls (155). The anti-NfL index correlated with disease duration (Spearman's R=0.42, p<0.0001) and the EDSS (R=0.54, p<0.0001). Although these correlations are moderate at best, the figures show that the findings were not based on outliers.
Applying his technique to the Amsterdam cohort at baseline we found a correlation of the anti-NfL index with MRI measures such as the PF (Spearman's R=-0.51, p<0.001), the T1 lesion load (R=0.37, p<0.05), the T2 lesion load (R=0.41, p<0.05) and the VF (R=0.37, p<0.05). For the anti-NfH index there was only a correlation with the PF (R=-0.39, p<0.05). These correlations were mainly based on the results for the RRMS subgroup were the anti-NfL index correlated with the PF, VF and T1LL (R=-0.56, p<0.05; R=0.72, p<0.01 and R=0.61, p<0.05, respectively). However, the results for the T1 & T2 lesion load and VF were partly based on 2-3 outliers [76] . With one exception (a weak correlation with the PF in the whole cohort, R=-0.39, p<0.05) no such correlations were found for the anti-NfH index [76] . 
